Psoriasis Journal Articles

 
 
  • Drug-induced Liver Injury in the Context of NAFLD How might certain drugs be more hepatotoxic in NAFLD patients? This article explores the pathophysiological mechanisms and reciprocity involved in NAFLD and drug-induced steatohepatitis.
  • Tildrakizumab for Moderate-to-Severe Plaque Psoriasis Is tildrakizumab therapy a safe and effective treatment option for moderate-to-severe plaque psoriasis?
  • Antinuclear Antibodies in Autoimmune Diseases Review the use and interpretation of antinuclear antibodies as diagnostic markers for autoimmune diseases in this primer.
  • Topical Trifarotene: A New Retinoid Trifarotene, a novel fourth-generation topical retinoid, shows favorable preliminary efficacy for acne, and may offer better tolerability than currently available drugs in this class.
  • Subcutaneous Methotrexate in Moderate-to-Severe Psoriasis A new study investigates the efficacy of an intensified two-step dosing schedule of subcutaneous methotrexate in patients with moderate-to-severe chronic plaque psoriasis.
  • NAFLD in Psoriasis: A Consequence of Inflammatory Burden? This review examines the role of chronic, low-grade inflammation in the pathogenesis of NAFLD in patients with psoriasis. Could biological therapies prevent progression of NAFLD in these patients?
  • The Evolution of Topical Formulations in Psoriasis A new vehicle for delivery of calcipotriol/betamethasone diproprionate, in the form of an aerosol foam, may increase adherence over ointments and gels for mild-to-moderate psoriasis.
  • Therapeutics for Adult Nail Psoriasis and Nail Lichen Planus Nail psoriasis and nail lichen planus can be stigmatizing and challenging to treat. This article presents an approach for selecting current topical and systemic therapies, including new biologics.
  • Obesity and Treatment Failure in Biologic-Treated UC Patients How does obesity impact real world response to biological therapy in patients with ulcerative colitis?
  • Psychological Stress and Psoriasis Its long been supposed that psychological stress aggravates psoriasis--but is there any convincing evidence to support this?
  • Janus Kinase Inhibitors: Emerging Applications in Dermatology Learn about the use of Janus kinase inhibitors, which have become promising treatment options for dermatologic conditions such as psoriasis, atopic dermatitis, alopecia areata, vilitigo, and more.
  • The Non-neuronal and Nonmuscular Effects of Botulinum Toxin New research suggests that botulinum neurotoxins may have a much wider range of both dermatological and nondermatological applications than originally thought.
  • Telerheumatology: The VA Experience This study assessed the diagnostic accuracy of telerheumatology as compared with face-to-face visits in a VA rheumatology clinic. Was the telerheumatology process well received by patients?
  • News for Pediatric Healthcare Providers From the FDA Which drugs have been newly developed or indicated for pediatric patients? Find out what there is to know.
  • Health Economics and Clinical Decision Making in Psoriasis While biological treatments for plaque psoriasis are highly effective and safe, they are also expensive. How can we prioritize their use while balancing cost-effectiveness?
  • HLA-Cw6 and Psoriasis What role does the HLA-Cw6 allele play in psoriasis? This review summarizes what we know concerning its relationship to epidemiology, pathogenesis, characteristics, and treatment implications.
  • Dermatologic Reactions to Immune Checkpoint Inhibitors Immune checkpoint inhibitors are a major breakthrough in cancer therapy, but may cause immune-related dermatologic adverse reactions. How do these commonly manifest and how should they be managed?
  • Managing Morbidity and Treatment-Related Toxicity in AS Find out more about the morbidities associated with ankylosing spondylitis and its treatment, and learn how to best manage them.
  • Ixekizumab Treatment for Psoriasis This study presents a comprehensive overview of the efficacy of ixekizumab therapy for moderate-to-severe plaque psoriasis, based on two ixekizumab dosing regimens from pivotal phase III studies.
  • Low Doses of Etanercept to Maintain Remission in PsA Find out how psoriatic arthritis patients who have achieved sustained remission with etanercept may benefit from a dosing interval increase.